Moreover, FFAR3 agonist (AR420626) treatment reduces enteropathy (ulcer formation and gastrointestinal bleeding) symptoms induced by indomethacin in rats by increasing duodenal HCO3- and GLP-2 hormonal synthesis whereas FFAR3 antagonist (CF3-MQC) counteract the AR420626 effect by reducing the enteropathy condition [147], indicating that the mucosal protective effect of AR420626 was mediated by FFA3 activation. The gene discussed is FFAR3; the disease is Abnormal intestine morphology.